Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000796882 | SCV000936415 | uncertain significance | Retinoblastoma | 2018-11-26 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine with glutamine at codon 42 of the RB1 protein (p.Leu42Gln). The leucine residue is moderately conserved and there is a moderate physicochemical difference between leucine and glutamine. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate insufficient coverage at this position in the ExAC database. This variant has not been reported in the literature in individuals with RB1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV004944157 | SCV005487664 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-10-07 | criteria provided, single submitter | clinical testing | The p.L42Q variant (also known as c.125T>A), located in coding exon 1 of the RB1 gene, results from a T to A substitution at nucleotide position 125. The leucine at codon 42 is replaced by glutamine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |